Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor

Sponsor
University of Leicester (Other)
Overall Status
Unknown status
CT.gov ID
NCT00003804
Collaborator
(none)
350
44
8

Study Details

Study Description

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for stage I Wilms' tumor.

PURPOSE: Randomized phase III trial to study the effectiveness of chemotherapy and surgery in treating children who are at risk of or who have stage I Wilms' tumor.

Condition or Disease Intervention/Treatment Phase
  • Biological: dactinomycin
  • Drug: vincristine sulfate
  • Procedure: conventional surgery
Phase 3

Detailed Description

OBJECTIVES: I. Determine the initial extension of disease, surgical procedures, gross and histological morphology, treatments, clinical outcome, and late consequences of therapy after treatment with neoadjuvant chemotherapy, surgery, and adjuvant chemotherapy with or without maintenance chemotherapy in patients with intermediate risk or anaplastic stage I Wilms' tumor. II. Determine the safety and effectiveness of reduced chemotherapy in these patients.

OUTLINE: This is a randomized, multicenter study. Patients receive dactinomycin IV on days 1-3 and 15-17 and vincristine IV on days 1, 8, 15, and 22. Patients then undergo surgery about a week after completion of chemotherapy. After surgery, patients receive vincristine IV on days 1, 8, 15, and 22 and dactinomycin IV on days 8-12. Patients are then randomized to one of two treatment arms after week 9. Arm I: Patients receive dactinomycin IV on days 1-5 of week 10 and vincristine IV on day 1 of both weeks 10 and 11. This course is repeated during weeks 17 and 18. Arm II: Patients receive no further treatment. Patients are followed every 3 months for 3 years, then annually thereafter. Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 350 patients (175 per treatment arm) will be accrued for this study within 7-8 years.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
350 participants
Allocation:
Randomized
Primary Purpose:
Treatment
Official Title:
Nephroblastoma Clinical Trial and Study
Study Start Date :
Jul 1, 1993

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 17 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    DISEASE CHARACTERISTICS: Initial diagnosis of a unilateral tumor with clinical and radiological characteristics of a nephroblastoma Histologically proven stage I Wilms' tumor after neoadjuvant treatment and surgery Intermediate risk or anaplastic No detectable distant metastases 4 weeks after adjuvant chemotherapy

    PATIENT CHARACTERISTICS: Age: 0.5 to 17 Performance status: Not specified Life expectancy:

    Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified

    PRIOR CONCURRENT THERAPY: See Disease Characteristics

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Clinique de l'Esperance Montegnee Belgium 4420
    2 Clinical Hospital Center Split Split Croatia 21000
    3 University Children Hospital Brno Czech Republic 662 63
    4 Aalborg Hospital Aalborg Denmark DK-9000
    5 Universtiy Hospital of Aarhus Aarhus Denmark 8200
    6 Odense University Hospital Odense Denmark DK-5000
    7 Hopital Nord Amiens Amiens France 80054
    8 CHR de Besancon - Hopital Saint-Jacques Besancon France 25030
    9 CHU de Bordeaux - Hopital Pellegrin Bordeaux France 33076
    10 C.H.U. de Brest Brest France 29200
    11 Centre Oscar Lambret Lille France 59020
    12 Centre Hospitalier Regional de Lille Lille France 59037
    13 Centre Hospital Regional Universitaire de Limoges Limoges France 87042
    14 Centre Leon Berard Lyon France 69373
    15 Hopital d'Enfants de la Timone Marseille France 13385
    16 Hopital Arnaud de Villeneuve Montpellier France 34295
    17 CHR Hotel Dieu Nantes France 44093
    18 Centre Antoine Lacassagne Nice France 06189
    19 C.H.U. Saint Etienne Hospital Nord Saint Etienne France 42055
    20 Hopitaux Universitaire de Strasbourg Strasbourg France 67091
    21 Centre Hospitalier Regional de Purpan Toulouse France 31059
    22 C.H. Bastien de Clocheville Tours France 3700
    23 CHRU de Nancy - Hopitaux de Brabois Vandoeuvre-Les-Nancy France 54511
    24 Children's Hospital A. Kyriakou Athens Greece 617
    25 Ospedale Raffaele Silvestrini San Sisto Perugia Italy 06100
    26 Academisch Medisch Centrum Amsterdam Netherlands 1105 AZ
    27 Academisch Ziekenhuis der Vrije Universiteit Amsterdam Netherlands 1117 MB
    28 Emma Kinderziekenhuis Amsterdam Netherlands NL-1100 DE
    29 University Medical Center Nijmegen Nijmegen Netherlands NL-6252 HB
    30 Haukeland Hospital - University of Bergen Bergen Norway N-5021
    31 University of Tromso Tromso Norway N-9037
    32 Regionsykehuset & University Hospital Trondheim Norway 7006
    33 Wroclaw Medical University Wroclaw (Breslau) Poland 50-367
    34 Hospital Escolar San Joao Porto Portugal 4200
    35 Pediatricna Klinika Ljubljana Slovenia 61000
    36 Hospital General Universitari Vall d'Hebron Barcelona Spain 08035
    37 Centro Medico "La Zarzuela" Madrid Spain 28023
    38 Hospital Universitario LaPaz Madrid Spain 28046
    39 Hospital Materno-Infantil Malaga Spain 29011
    40 Hospital General de Galicia Santiago de Compostela Spain 15705
    41 Hospital Des Cruces Vizcaya Spain 48
    42 Lund University Hospital Lund Sweden SE-22-1 85
    43 Karolinska Hospital Stockholm Sweden S-171 76
    44 Tawam Hospital Abu Dhabi United Arab Emirates

    Sponsors and Collaborators

    • University of Leicester

    Investigators

    • Study Chair: Jan DeKraker, MD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University of Leicester
    ClinicalTrials.gov Identifier:
    NCT00003804
    Other Study ID Numbers:
    • CDR0000066948
    • SIOP-93-01
    • EU-98064
    First Posted:
    Jul 16, 2004
    Last Update Posted:
    Jun 24, 2014
    Last Verified:
    Apr 1, 2012
    Keywords provided by University of Leicester
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 24, 2014